Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2021 / N 2

COVID-19 и болезнь Альцгеймера
А.Н. Боголепова

References

1. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. European Journal of Neurology 2018 Jan;25(1):59-70.
2. Cahill S. WHO’s global action plan on the public health response to dementia: some challenges and opportunities. Aging & Mental Health 2020 Feb;24(2):197-9.
3. Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimer’s Research & Therapy 2020 Dec;12(1):170.
4. Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. Journal of Alzheimer’s Disease 2020;76(1):3-19.
5. Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J, Lapperre T, Porsberg CM. Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. European Neuropsychopharmacology 2021 May;46:39-48.
6. Amalakanti S, Arepalli KVR, Jillella JP. Cognitive assessment in asymptomatic COVID-19 subjects. Virusdisease 2021 Feb;32(1):1-4.
7. Kas A, Soret M, Pyatigoskaya N, Habert MO, Hesters A, Le Guennec L, Paccoud O, Bombois S, Delorme C; CoCo-Neurosciences study group and COVID SMIT PSL study group. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging 2021 Jan 15;1-15. doi: 10.1007/s00259-020-05178-y. Online ahead of print.
8. Ciaccio M, Lo Sasso B, Scazzone C, Gambino CM, Ciaccio AM, Bivona G, Piccoli T, Giglio RV, Agnello L. COVID-19 and Alzheimer’s disease. Brain Sciences 2021 Feb;11(3):305.
9. Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. The American Journal of Physiology. Regulatory Integrative and Comparative Physiology 2007 Jan;292(1):R373-81.
10. Chen R, Wang K, Yu J, Chen Z, Wen C, Xu Z. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. bioRxiv 2020. doi: 10.1101/2020.04.07.030650. Posted Apr 09 2020.
11. Alenina N, Bader M. ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models. Neurochemical Research 2019 Jun;44(6):1323-9.
12. Li Y, Fu L, Gonzales DM, Lavi E. Coronavirus neurovirulence correlates with the ability of the virus to induce proinflammatory cytokine signals from astrocytes and microglia. Journal of Virology 2004 Apr;78(7):3398-406.
13. Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010 Oct;7(4):354-65.
14. Lim KH, Yang S, Kim SH, Joo JY. Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer’s disease. The Journal of Infection 2020 Sep;81(3):e33-4.
15. Steardo L, Steardo L, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiologica (Oxford, England) 2020 Jul;229(3):e13473.
16. Wen Y, Yang S, Liu R, Simpkins JW. Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Research 2004 Oct;1022(1-2):30-8.
17. Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical cross-talk between COVID-19 and Alzheimer’s disease. Molecular Neurobiology 2021 Mar;58(3):1017-23.
18. McAlpine LS, Fesharaki-Zadeh A, Spudich S. Coronavirus disease 2019 and neurodegenerative disease: what will the future bring? Current Opinion in Psychiatry 2021 Mar;34(2):177-85.
19. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, Lang C, Xiao Q, Xiao K, Yi Z, Qiang M, Xiang J, Zhang B, Chen Y. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv 2020. doi: 10.1101/2020.02.10.20021832. Posted Feb 20 2020.
20. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiology of Aging 1996 Sep-Oct;17(5):761-6.
21. Goshen I, Kreisel T, Ounallah-Saad H, Renbaum P, Zalzstein Y, Ben-Hur T, Levy-Lahad E, Yirmiya R. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 2007;32(8-10):1106-15.
22. Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Research & Therapy 2020 Jun;12(1):69.
23. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine 2016 Jun;8(6):595-608.
24. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD. The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010 Mar;5(3):e9505.
25. Agnello L, Piccoli T, Vidali M, Cuffaro L, Sasso BL, Iacolino G, Giglio VR, Lupo F, Alongi P, Bivona G, Ciaccio M. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. Scandinavian Journal of Clinical and Laboratory Investigation 2020 Jul;80(4):313-7.
26. Ameres M, Brandstetter S, Toncheva AA, Kabesch M, Leppert D, Kuhle J, Wellmann S. Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. Journal of Neurology 2020 Dec;267(12):3476-8.
27. Edén A, Kanberg N, Gostner J, Fuchs D, Hagberg L, Andersson LM, Lindh M, Price RW, Zetterberg H, Gisslén M. CSF biomarkers in patients with COVID-19 and neurological symptoms: a case series. Neurology 2021 Jan;96(2):e294-300.
28. Jin M, Cao L, Dai YP. Role of neurofilament light chain as a potential biomarker for Alzheimer’s disease: a correlative meta-analysis. Frontiers in Aging Neuroscience 2019 Sep;11:254.
29. Abate G, Memo M, Uberti D. Impact of COVID-19 on Alzheimer’s disease risk: viewpoint for research action. Healthcare (Basel, Switzerland) 2020 Aug;8(3):286.
30. Kuo CL, Pilling LC, Atkins JL, Masoli J, Delgado J, Kuchel GA, Melzer D. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. The Journals of Gerontology. Series A: Biological Sciences and Medical Sciences 2020 Oct;75(11):2231-2.
31. Tzioras M, Davies C, Newman A, Jackson R, Spires-Jones T. Invited review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer’s disease. Neuropathology and Applied Neurobiology 2019 Jun;45(4):327-46.
32. Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, Pachicano M, Joe E, Nelson AR, D’Orazio LM, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Reiman EM, Caselli RJ, Chui H, Tcw J, Chen Y, Pa J, Conti PS, Law M, Toga AW, Zlokovic BV. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 2020 May;581(7806):71-6.
33. Evans CE, Miners JS, Piva G, Willis CL, Heard DM, Kidd EJ, Good MA, Kehoe PG. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease. Acta Neuropathologica 2020 Mar;139(3):485-502.
34. Palmer K, Monaco A, Kivipelto M, Onder G, Maggi S, Michel JP, Prieto R, Sykara G, Donde S. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing. Aging Clinical and Experimental Research 2020 Jul;32(7):1189-94.
35. Deng J, Zhou F, Hou W, Silver Z, Wong CY, Chang O, Huang E, Zuo QK. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Annals of the New York Academy of Sciences 2021 Feb;1486(1):90-111.
36. Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Depression as a risk factor for cognitive impairment in later life: the Health In Men cohort study. International Journal of Geriatric Psychiatry 2016 Apr;31(4):412-20.
37. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. Memantine for dementia. The Cochrane Database of Systematic Reviews 2019 Mar;3(3):CD003154.
38. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG. Anti-inflammatory effects of amantadine and memantine: possible therapeutics for the treatment of Covid-19? Journal of Personalized Medicine 2020 Nov;10(4):217.
39. Leung JM, Yang CX, Sin DD. COVID-19 and nicotine as a mediator of ACE-2. The European Respiratory Journal 2020 Jun;55(6):2001261.
40. Hasanagic S, Serdarevic F. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond. The European Respiratory Journal 2020 Aug;56(2):2001610.
41. Singh Tomar PP, Arkin IT. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by gliclazide and memantine. Biochemical and Biophysical Research Communications 2020 Sep;530(1):10-4.
42. Wu HM, Tzeng NS, Qian L, Wei SJ, Hu X, Chen SH, Rawls SM, Flood P, Hong JS, Lu RB. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009 Sep;34(10):2344-57.
43. Wang F, Zou Z, Gong Y, Yuan D, Chen X, Sun T. Regulation of human brain microvascular endothelial cell adhesion and barrier functions by memantine. Journal of Molecular Neuroscience 2017 May;62(1):123-9.
44. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases, multiple sclerosis, parkinsonism and cognitive impairment. Multiple Sclerosis and Related Disorders 2020 Jul;42:102163.
45. Hirano K, Fujimaki M, Sasazawa Y, Yamaguchi A, Ishikawa KI, Miyamoto K, Souma S, Furuya N, Imamichi Y, Yamada D, Saya H, Akamatsu W, Saiki S, Hattori N. Neuroprotective effects of memantine via enhancement of autophagy. Biochemical and Biophysical Research Communications 2019 Oct;518(1):161-70.
46. Folch J, Busquets O, Ettcheto M, Sánchez-López E, Castro-Torres RD, Verdaguer E, Garcia ML, Olloquequi J, Casadesús G, Beas-Zarate C, Pelegri C, Vilaplana J, Auladell C, Camins A. Memantine for the treatment of dementia: a review on its current and future applications. Journal of Alzheimers Disease 2018;62(3):1223-40.
47. Long JD, Liu Y, Jiao DL, Wang YJ, Zan GY, Ju YY, Zhao M, Liu G. The neuroprotective effect of memantine on methamphetamine-induced cognitive deficits. Behavioral Brain Research 2017 Apr;323:133-40.
48. Sun L, Zhou M, Liu C, Tang Y, Xiao K, Dai J, Gao Z, Siew L, Cao G, Wu X, Li L, Zhang R. Memantine can relieve the neuronal impairment caused by neurotropic virus infection. Journal of Medical Virology 2019 Jun;91(6):935-40.
49. Ilhan Algin D, Dagli Atalay S, Ozkan S, Ozbabalik Adapinar DO, Sivrioz IA. Memantine improves semantic memory in patients with amnestic mild cognitive impairment: a single-photon emission computed tomography study. Journal of International Medical Research 2017 Dec;45(6):2053-64.
50. Peters O, Lorenz D, Fesche A, Schmidtke K, Hüll M, Perneczky R, Rüther E, Möller HJ, Jessen F, Maier W, Kornhuber J, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Teipel S, Wellek S, Frölich L, Heuser I. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. The Journal of Nutrition. Health & Aging 2012;16(6):544-8.
51. Levin O, Yunishchenko N, Dudarova M. Efficacy of akatinol memantine in moderate cognitive impairments. Neuroscience and Behavioral Physiology 2010 Oct;40(8):926-33.
52. Pelton GH, Harper OL, Roose SP, Marder K, D’Antonio K, Devanand DP. Combined treatment with memantine/escitalopram for older depressed patients with cognitive impairment: a pilot study. International Journal of Geriatric Psychiatry 2016;31:648-55.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]